Palifermin
- Generic Name
- Palifermin
- Brand Names
- Kepivance
- Drug Type
- Biotech
- CAS Number
- 162394-19-6
- Unique Ingredient Identifier
- QMS40680K6
Overview
Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.
Background
Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.
Indication
For treatment of oral mucositis associated with chemotherapy and radiation therapy.
Associated Conditions
- Oral Mucositis
Research Report
Palifermin Report
Name: Palifermin Name (English): Palifermin DrugBank ID: DB00039 Type: Biotech CAS Number: 162394-19-6
Palifermin is a recombinant human keratinocyte growth factor (KGF) comprised of 140 amino acid residues. It is produced using E. coli. Palifermin binds to the human keratinocyte growth factor (KGF) receptor on epithelial cell surfaces. This action stimulates epithelial cell proliferation, differentiation, and migration, thereby protecting and promoting healing of tissues lining the mouth and gastrointestinal tract.
Indication: To decrease the incidence, duration, and severity of oral mucositis in adult patients with hematologic malignancies receiving myeloablative radiochemotherapy requiring hematopoietic stem cell support.
Pharmacology: Palifermin acts as both a cell growth and survival factor. It promotes cell proliferation and upregulates cytoprotective mechanisms.
Contraindications: No specific contraindications are listed in the provided data.
Adverse Effects: Common side effects include thickening of oral mucosa, flushing, and dysgeusia. Other reported side effects include swelling, pain (including joint pain), increase in blood pancreas enzymes, increased blood pressure, and proteinuria. Serious side effects may include difficulty breathing and changes in cutaneous or mucous membrane appearance/feel.
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.